InsiderSignalSign in

← Insider buys

FATE

Fate Therapeutics, Inc. · Healthcare

Insiders sold $306K of Fate Therapeutics, Inc. in the last 12 months and bought none

$0Bought, 12 mo

$306KSold, 12 mo

$246.8MMarket cap

FATE over the last year

No insider buys filed in this year

FATE after insider buys

3 months after each buy, from the first price a copier could get.

−6.3%Average

−12.0 ptsVs S&P 500

2 of 5Higher

5 buys since 2019 with 3 months of prices.

Every filing

116 insider filings since 2017, newest first

Cindy Tahl · Insider

$95K−6.2%Aug 5

Bahram Valamehr · President and CEO

$108K−6.9%Aug 5

Cindy Tahl · Insider

$48K−4.0%May 21

Bahram Valamehr · President and CEO

$54K−4.0%May 21

Redmile Group, LLC · Director and 10% owner

$669K+3.0%Dec 26

Cindy Tahl · General Counsel and Secretary

$48K−7.0%Jan 10

Bahram Valamehr · Chief R, D Officer

$49K−7.0%Jan 10

J Scott Wolchko · President and CEO

$63K−4.0%Jan 10

Edward J Dulac III · CFO

$31K−6.0%Jan 10

Redmile Group, LLC · Director and 10% owner

Cindy Tahl · General Counsel and Secretary

$58K−14.0%Nov 13

Edward J Dulac III · CFO

$25K−4.0%Jul 6

Redmile Group, LLC · Director and 10% owner

$1.7M+2.0%Apr 21

Redmile Group, LLC · Director and 10% owner

John Mendlein · Director

$698K+79.0%Jan 13

Cindy Tahl · General Counsel and Secretary

$61K−6.0%Jan 11

J Scott Wolchko · President and CEO

$241K−11.0%Jan 11

Bahram Valamehr · Chief R, D Officer

$57K−6.0%Jan 11

Edward J Dulac III · CFO

$38K−5.0%Jan 11

Yu-Waye Chu · Chief Medical Officer

$41K−5.0%Jan 11

Edward J Dulac III · CFO

$153K−4.0%Aug 19

J Scott Wolchko · President and CEO

$1.2M−8.0%Jul 25

Bahram Valamehr · Chief R, D Officer

$519K−9.0%Jul 8

Bahram Valamehr · Chief R, D Officer

$236K−4.0%Jul 7

Mark Plavsic · Chief Technical Officer

$92K−3.0%Jul 6

John Mendlein · Director

$31K−1.0%Jun 6

Karin Jooss · Director

$34K−55.0%Jun 6

Timothy Coughlin · Director

$33K−2.0%Jun 6

Cindy Tahl · General Counsel and Secretary

$574K−12.0%Jun 2

J Scott Wolchko · President and CEO

$1.4M−8.0%Apr 25

Yu-Waye Chu · Chief Medical Officer

$144K−3.0%Apr 21

Cindy Tahl · General Counsel and Secretary

$971K−12.0%Apr 4

Bahram Valamehr · Chief R, D Officer

$777K−12.0%Mar 15

John Mendlein · Director

$1.1M−17.0%Mar 11

J Scott Wolchko · President and CEO

$1.6M−8.0%Jan 24

Cindy Tahl · General Counsel and Secretary

$263K−3.0%Jan 13

J Scott Wolchko · President and CEO

$709K−3.0%Jan 13

Bahram Valamehr · Chief R, D Officer

$222K−3.0%Jan 13

Edward J Dulac III · CFO

$86K−2.0%Jan 13

Yu-Waye Chu · SVP Clinical Development

$192K−3.0%Jan 13

Cindy Tahl · General Counsel and Secretary

$359K−5.0%Jan 12

J Scott Wolchko · President and CEO

$1.6M−7.0%Jan 12

Bahram Valamehr · Chief R, D Officer

$260K−4.0%Jan 12

Cindy Tahl · General Counsel and Secretary

$3.0M−23.0%Jan 4

Edward J Dulac III · CFO

$959K−13.0%Dec 21

Bahram Valamehr · Chief R, D Officer

$1.2M−14.0%Dec 14

Yu-Waye Chu · SVP Clinical Development

$386K−6.0%Dec 13

J Scott Wolchko · President and CEO

$1.1M−4.0%Nov 22

J Scott Wolchko · President and CEO

$3.6M−13.0%Oct 25

Cindy Tahl · General Counsel and Secretary

$2.9M−32.0%Oct 4

About Fate Therapeutics, Inc.

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tumors. It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. The company was incorporated in 2007 and is headquartered in San Diego, California.

Filings come from SEC EDGAR and prices from daily closes. Not investment advice.